Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
McKinsey
McKesson

Last Updated: September 26, 2022

Details for Patent: 8,084,047


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,084,047 protect, and when does it expire?

Patent 8,084,047 protects XIIDRA and is included in one NDA.

This patent has thirty-five patent family members in fifteen countries.

Summary for Patent: 8,084,047
Title:Compositions and methods for treatment of eye disorders
Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Inventor(s): Shen; Wang (San Mateo, CA), Oslob; Johan D. (Sunnyvale, CA), Barr; Kenneth (Boston, MA), Zhong; Min (Foster City, CA)
Assignee: Sarcode Bioscience Inc. (Brisbane, CA)
Application Number:12/508,367
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,084,047
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Dosage form; Delivery;

Drugs Protected by US Patent 8,084,047

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,084,047

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006247136 See Plans and Pricing
Canada 2609053 See Plans and Pricing
Canada 2960117 See Plans and Pricing
Canada 2985444 See Plans and Pricing
China 101175488 See Plans and Pricing
China 102617557 See Plans and Pricing
Cyprus 1116045 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
McKinsey
Medtronic
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.